Two Drugs (#Apalutamide and #Enzalutamide) Offer Hope Against a Tough-to-Treat Prostate Cancer

THURSDAY, Feb. 8, 2018 -- Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows. Both a newly developed drug called apalutamide and an already approved drug called...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Condition:   High Risk Prostate Cancer Interventions:   Diagnostic Test: Whole body contrast enhanced computer tomography;   Diagnostic Test: 99mTC-HMDP planar bone scintigraphy (BS);   Diagnostic Test: 99mTc-HMDP single photon emission computer tomography/computer tomography;   Diagnostic Test: Whole-body magnetic resonance imaging;   Diagnostic Test: Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography Sponsors:   Turku University Hospital;   University of Turku Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Afro-Caribbean populations in French West Indies share the same major clinical and pathological risk factors of BCR after RP identified in other ethnic groups. Perioperative blood loss appears to be an additional and independent predictive factor of BCR. LEVEL OF PROOF: 4. PMID: 29789237 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
CONCLUSION: A reduction of LUTS is observed in patients with locally advanced or metastatic prostate cancer treated with triptorelin in routine practice. This is in agreement with similar observational studies of triptorelin conducted in other countries. LEVEL OF PROOF: 4. PMID: 29789236 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
CONCLUSION: Mp-MRI is a useful exam for selecting patients eligible for AS even if the situation remains unclear after prostate biopsies including targeted biopsies. Upon confirmation by further studies, mp-MRI should be considered as an independent criterion before entering an AS program. LEVEL OF EVIDENCE: 4. PMID: 29789235 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
CONCLUSIONS: In this study obese men do not appear to have a significant increase in risk of PSMs at RP compared to lean and overweight men when operated by a minimally invasive approach. The magnified vision and increased access to the pelvis allowed by a laparoscopic and robotic-assisted approach may be accountable for our findings. Larger studies are needed to validate our results. LEVEL OF PROOF: 4. PMID: 29789234 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Is active surveillance for low-risk prostate cancer preferred in men who strongly want to preserve sexual function?Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Publication date: Available online 24 May 2018 Source:Journal of Applied Biomedicine Author(s): Patrícia Borba Martiny, Diego Duarte Alcoba, Brasil Silva Neto, Paulo Costa Carvalho, Ilma Simoni Brum Prostate cancer (PCa) is the second most frequent cancer in men worldwide. Distinguishing between the nonaggressive and aggressive forms of this disease is difficult, and a means to better characterize molecular patterns that could aid in diagnosis is urgently needed. Here, we compare the proteomic profiles of PCa and benign prostatic hyperplasia (BPH) in an effort to elucidate underlying mechanisms of oncogenesis. We c...
Source: Journal of Applied Biomedicine - Category: Biotechnology Source Type: research
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Giovanni Lughezzani, Nicolo’ Maria Buffi, Massimo Lazzeri
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Vincenza Conteduca, Giorgia Gurioli, Ugo De Giorgi
Source: European Urology - Category: Urology & Nephrology Source Type: research
Erleada (apalutamide) is the first treatment approved for nonmetastatic, castration-resistant prostate cancer.If patients prescribed apalutamide are also taking other drugs metabolized by the same cytochrome P-450 isoenzyme systems, the circulating levels of apalutamide may be altered.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
More News: Cancer | Cancer & Oncology | General Medicine | Prostate Cancer